Table 1.

Patient characteristics according to treatment sequence

Patient characteristic	Latanoprost/latanoprost–timolol n = 1592	Bimatoprost/bimatoprost–timolol n = 110	Travoprost/travoprost–timolol n = 114	P-value
Gender
Male	48.8%	45.5%	50.9%	0.71
Female	51.2%	54.5%	49.1%
Age (year)	68.3	68.2	68.8	0.95
Time since diagnosis (years)	4.34	4.24	3.57	0.12
Mean duration of follow-up (days)	1584.46	638.19	798.94	<0.001